Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cellmid (CDY) subsidiary, Advangen, has signed a distribution agreement with Tru Beauty Concepts for its anti-aging hair care products, évolis
  • Tru Beauty is a salon distributor that services 40,000 salons across the U.S.
  • Under the agreement, Tru Beauty will sell the évolis range to salons in northeast America for five years
  • Cellmid is up four per cent on the market today and shares are trading for 13 cents per share

Cellmid (CDY) subsidiary, Advangen, has signed a distribution agreement with Tru Beauty Concepts for its anti-aging hair care products, évolis.

Tru Beauty is a salon distributor and national educator, servicing 40,000 salons through the United States.

Under the agreement, Tru Beauty will sell the évolis range to salons in northeast America for five years.

évolis will also be listed on the Salon Interactive portal, which is an e-commerce hub for hair salons across the U.S. This deal is expected to result in significant revenue growth in the U.S. business during the second half of the 2021 financial year.

CEO Maria Halasz says this agreement is a “game-changer.”

“Securing salon distribution will add scale to our U.S. expansion and growth ambitions for the brand,” she added.

The deal comes as consumer health services in the U.S. increased by 51 per cent to $626,000 over FY20.

Cellmid is up four per cent on the market this afternoon and shares are trading for 13 cents per share at 1:26 pm AEST.

CDY by the numbers
More From The Market Herald
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion (ASX:ALC) to raise $55m & acquire Silverlink

Alcidion (ALC) has announced plans to raise $55 million and buy patient software specialists, Silverlink PCS Software.
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay

" Actinogen Medical (ASX:ACW) partners with Oxford University

Actinogen (ACW) has announced a collaboration with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS).
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) soars on ‘positive’ Rett syndrome trial results

Neuren Pharmaceuticals’ (NEU) shares have soared following positive top-line results from a phase three study on Rett syndrome.

" Recce Pharmaceuticals (ASX:RCE) spikes amid trial update

Shares in Recce Pharmaceuticals (RCE) have spiked amid a positive update in the clinical trial for the treatment of burn wound infections.